公开(公告)号：US20240360239A1

公开(公告)日：2024-10-31

申请号：US18644984

申请日：2024-04-24

Applicant: Kling Biotherapeutics B.V.

Inventor： Hergen SPITS ,  Paula Maria Wilhelmina VAN HELDEN ,  Remko SCHOTTE ,  Wouter POS ,  Christien FATMAWATI ,  Danïel Michiel GO ,  Koen WAGNER ,  Julien Christian VILLAUDY

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  G01N33/574

CPC classification number: C07K16/2896 ,  A61P35/00 ,  C07K14/70596 ,  C07K16/2818 ,  G01N33/57492 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  G01N2333/70596

Abstract: The present invention provides novel binding compounds and therapeutic applications thereof.

公开(公告)号：US12129292B2

公开(公告)日：2024-10-29

申请号：US17438657

申请日：2020-02-26

Applicant: Janssen Biotech, Inc.

Inventor： Kristopher Barnthouse ,  Subinay Ganguly ,  Maarten Groeneveld ,  Manuel Lopez ,  Michael Nedved ,  Kevin D. Smith

IPC: C07K16/24

CPC classification number: C07K16/241 ,  C07K2317/14 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Presented here are methods for producing a recombinant anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:38 and a light chain (LC) comprising SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.

公开(公告)号：US20240352132A1

公开(公告)日：2024-10-24

申请号：US18579344

申请日：2022-07-14

Applicant: Jiangsu Hengrui Pharmaceuticals Co., Ltd. ,  Shanghai Hengrui Pharmaceutical Co., Ltd.

Inventor： Xin YE ,  Le SUN ,  Weiwei ZHANG ,  Weikang TAO

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47

CPC classification number: C07K16/2863 ,  A61P35/00 ,  C07K14/4716 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/30

Abstract: An antigen-binding molecule specifically binding to HGFR and EGFR, and the pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.

公开(公告)号：US20240343802A1

公开(公告)日：2024-10-17

申请号：US18612960

申请日：2024-03-21

Applicant: ZYMEWORKS BC INC.

Inventor： Gordon Yiu Kon Ng ,  Surjit Bhimarao Dixit ,  Thomas Spreter von Kreudenstein ,  Nina E. Weisser

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2809 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

公开(公告)号：US20240342279A1

公开(公告)日：2024-10-17

申请号：US18507995

申请日：2023-11-13

Applicant: Seagen Inc.

Inventor： Ana Paula Galvao da Silva ,  Julie DeSander ,  Jeffrey Behrens ,  Darius Ghaderi ,  Mai Zhang ,  Kristan Meetze

IPC: A61K39/395 ,  A61K31/401 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K16/44

CPC classification number: A61K39/39558 ,  C07K16/3015 ,  C07K16/3046 ,  C07K16/44 ,  A61K31/401 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77

Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.

公开(公告)号：US20240336699A1

公开(公告)日：2024-10-10

申请号：US18750233

申请日：2024-06-21

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Sonny Oon ANG ,  Enli LIU ,  Elizabeth SHPALL ,  Katy REZVANI

IPC: C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P37/06 ,  C07K14/54 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  C12N15/52 ,  C12N15/86

CPC classification number: C07K16/2896 ,  A61K35/17 ,  A61P37/06 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2803 ,  C07K16/2863 ,  C12N15/52 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

Abstract: Provided herein are chimeric antigen receptors (CARs) comprising a truncated EGFRvIII (Ev3) in the hinge region of the CAR and/or a humanized scFv. Further provided herein are immune cells expressing the CARs as well as methods of their use in the treatment of immune disorders.

公开(公告)号：US12110332B2

公开(公告)日：2024-10-08

申请号：US16765008

申请日：2017-11-20

Applicant: Taizhou Mabtech Pharmaceutical Co., Ltd.

Inventor： Yajun Guo

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/705

CPC classification number: C07K16/2827 ,  A61P35/00 ,  A61P37/02 ,  C07K14/70503 ,  C07K16/2896 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2319/70

Abstract: A bifunctional fusion protein targeting CD47 and PD-L1, which belongs to the field of biomedicine and solves the problems that anti-PD-1/PD-L1 treatment has poor effect on low immunogenic tumors and anti-CD47 treatment has poor targeting properties. The fusion protein consists of a CD47-binding moiety and a PD-L1-binding moiety linked by means of a disulfide bond, can block both the binding of CD47 to SIRPa and the binding of PD-L1 to PD-1, not only activating macrophage phagocytosis of tumor cells and promoting antigen presentation in innate immunity, but also promoting tumor-specific T cell activation in acquired immunity, and has lower hematological toxicity. The fusion protein has better anti-tumor efficacy and hematological safety than anti-PD-L1 or anti-CD47 therapy alone, and animals from which a tumor has disappeared after the treatment of the fusion protein produce immunity against re-inoculation of the same tumor cell.

公开(公告)号：US20240327537A1

公开(公告)日：2024-10-03

申请号：US18664078

申请日：2024-05-14

Applicant: KisoJi Biotechnology Inc.

Inventor： Wenyang HOU ,  Shugang YAO ,  Luis DA CRUZ ,  David S. YOUNG

IPC: C07K16/30

CPC classification number: C07K16/30 ,  C07K2317/569 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

公开(公告)号：US20240317874A1

公开(公告)日：2024-09-26

申请号：US18572710

申请日：2022-06-28

Applicant: HIFIBIO (HK) LIMITED

Inventor： Francisco Adrian ,  Liang Schweizer ,  Qian Zhang ,  Yun-Yueh Lu ,  Andreas Raue

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K47/6849 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/732 ,  C07K2317/75

Abstract: Provided is a novel anti-OX40 antibody, including the compositions of anti-OX40 antibody, a polynucleotide encoding the anti-OX40 antibody, methods of preparing the anti-OX40 antibody, and methods of using the anti-OX40 antibody.

公开(公告)号：US20240309109A1

公开(公告)日：2024-09-19

申请号：US18418804

申请日：2024-01-22

Applicant: MORPHOSYS AG

Inventor： Michael TESAR ,  Ute JÄGER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/3061 ,  C07K16/2896 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732

Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.